Don’t miss the latest developments in business and finance.

Lupin receives USFDA approval for Clobazam Oral Suspension, 2.5 mg/mL

Image
Capital Market
Last Updated : Dec 31 2018 | 6:31 PM IST
Lupin announced that it has received approval for its Clobazam Oral Suspension, 2.5 mg/mL from the United States Food and Drug Administration (FDA) to market a generic version of Lundbeck Pharmaceuticals LLC's Onfi Oral Suspension, 2.5 mg/ml.

Lupin's Clobazam Oral Suspension, 2.5 mg/mL is the generic version of Lundbeck Pharmaceuticals, LLC's Onfi Oral Suspension, 2.5 mg/ml. It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.

Clobazam Oral Suspension, 2.5 mg/mL had annual sales of approximately USD 260.2 million in the US (IQVIA MAT September 2018).

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Dec 31 2018 | 6:06 PM IST

Next Story